A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Nygårdas, Michaela ^a   Paavilainen, Henrik ^a   Müther, Nadine ^b,c   Nagel, Claus Henning ^b,d   Röyttä, Matias ^a   Sodeik, Beate ^b   Hukkanen, Veijo ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Novartis Vaccines and Diagnostics GmbH   (Germany)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; HERPESVIRUS VECTOR; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; VIRUS DNA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BACTERIAL ARTIFICIAL CHROMOSOME; CELL COUNT; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PROTEIN EXPRESSION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; AUTOIMMUNITY; BRAIN; CERCOPITHECUS AETHIOPS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; LEUKEMIA INHIBITORY FACTOR; MICE; MYELIN SHEATH; OLIGODENDROGLIA; RNA, MESSENGER; SIMPLEXVIRUS; SPINAL CORD; VERO CELLS; VIRUS REPLICATION;

EID: 84877904363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064200     Document Type: Article

References (59)

1. Frampton AJ, Goins W, Nakano K, Burton E, Glorioso J, (2005) HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 12: 891-901.
2. Manservigi R, Argnani R, Marconi P, (2010) HSV Recombinant Vectors for Gene Therapy. Open Virol J 4: 123-156.
3. Chou J, Kern ER, Whitley RJ, Roizman B, (1990) Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250: 1262-1266.
4. Chou J, Roizman B, (1992) The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A 89: 3266-3270.
5. Whitley R, Kern E, Chatterjee S, Chou J, Roizman B, (1993) Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 91: 2837-2843.
6. Markovitz N, Baunoch D, Roizman B, (1997) The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1. J Virol 71: 5560-5569.
7. He B, Gross M, Roizman B, (1997) The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 94: 843-848.
8. Verpooten D, Ma Y, Hou S, Yan Z, He B, (2009) Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 protein of herpes simplex virus 1. J Biol Chem 284: 1097-1105.
9. Andreansky S, He B, van Cott J, McGhee J, Markert J, et al. (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5: 121-130.
10. Martuza RL, (2000) Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 105: 841-846.
11. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, et al. (2011) Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 21: 213-226.
12. Furlan R, Poliani P, Galbiati F, Bergami A, Grimaldi L, et al. (1998) Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum Gene Ther 9: 2605-2617.
13. Broberg E, Setälä N, Röyttä M, Salmi A, Erälinna J, et al. (2001) Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther 8: 769-777.
14. Nygårdas M, Aspelin C, Paavilainen H, Röyttä M, Waris M, et al. (2011) Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5. Gene Ther 18: 646-655.
15. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG, (2000) Multiple sclerosis. N Engl J Med 343: 938-952.
16. Zamvil S, Steinman L, (1990) The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8: 579-621.
17. Langrish C, Chen Y, Blumenschein W, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
18. Kennedy M, Torrance D, Picha K, Mohler K, (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149: 2496-2505.
19. Cua DJ, Hinton DR, Stohlman SA, (1995) Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-resistant mice. Th2-mediated suppression of autoimmune disease. J Immunol 155: 4052-4059.
20. O'Connor RA, Anderton SM, (2008) Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 193: 1-11.
21. Sakaguchi S, (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562.
22. Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K, (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162: 1-11.
23. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
24. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
25. Comi G, Filippi M, Wolinsky JS, (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49: 290-297.
26. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, et al. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8: 987-997.
27. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-294.
28. Gearing DP, Thut CJ, VandeBos T, Gimpel SD, Delaney PB, et al. (1991) Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J 10: 2839-2848.
29. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, et al. (1992) The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434-1437.
30. Metcalf D, (2003) The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21: 5-14.
31. Brown MA, Metcalf D, Gough NM, (1994) Leukaemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine 6: 300-309.
32. Kerr BJ, Patterson PH, (2005) Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 51: 73-79.
33. Azari MF, Profyris C, Karnezis T, Bernard CC, Small DH, et al. (2006) Leukemia inhibitory factor arrests oligodendrocyte death and demyelination in spinal cord injury. J Neuropathol Exp Neurol 65: 914-929.
34. Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, et al. (2008) Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 8: 1237-1247.
35. Sugiura S, Lahav R, Han J, Kou SY, Banner LR, et al. (2000) Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci 12: 457-466.
36. Mahic M, Kalland ME, Aandahl EM, Torgersen KM, Taskén K, (2008) Human naturally occurring and adaptive regulatory T cells secrete high levels of leukaemia inhibitory factor upon activation. Scand J Immunol 68: 391-396.
37. Gao W, Thompson L, Zhou Q, Putheti P, Fahmy TM, et al. (2009) Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 8: 1444-1450.
38. Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, et al. (2006) Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J Neurosci Res 83: 763-774.
39. Butzkueven H, Zhang J, Soilu-Hanninen M, Hochrein H, Chionh F, et al. (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8: 613-619.
40. Butzkueven H, Emery B, Cipriani T, Marriott M, Kilpatrick T, (2006) Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 53: 696-703.
41. Gresle MM, Alexandrou E, Wu Q, Egan G, Jokubaitis V, et al. (2012) Leukemia Inhibitory Factor Protects Axons in Experimental Autoimmune Encephalomyelitis via an Oligodendrocyte-Independent Mechanism. PLoS One 7: e47379.
42. Slaets H, Hendriks JJ, Van den Haute C, Coun F, Baekelandt V, et al. (2010) CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Mol Ther 18: 684-691.
43. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH, (1997) Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A 94: 14759-14763.
44. Adler H, Messerle M, Koszinowski UH, (2003) Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev Med Virol 13: 111-121.
45. Nagel CH, Döhner K, Fathollahy M, Strive T, Borst EM, et al. (2008) Nuclear egress and envelopment of herpes simplex virus capsids analyzed with dual-color fluorescence HSV1(17+). J Virol 82: 3109-3124.
46. Sandbaumhüter M, Döhner K, Schipke J, Binz A, Pohlmann A, et al. (2012) Cytosolic herpes simplex virus capsids not only require binding inner tegument protein pUL36 but also pUL37 for active transport prior to secondary envelopment. Cell Microbiol doi: 10.1111/cmi.12075.
47. Abramoff MD, Magelhaes PJ, Ram SJ, (2004) Image Processing with ImageJ. Biophotonics International 11: 36-42.
48. Broberg E, Setälä N, Erälinna J, Salmi A, Röyttä M, et al. (2002) Herpes simplex virus type 1 infection induces upregulation of interleukin-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice. J Interferon Cytokine Res 22: 641-651.
49. Hukkanen V, Rehn T, Kajander R, Sjöroos M, Waris M, (2000) Time-resolved fluorometry PCR assay for rapid detection of herpes simplex virus in cerebrospinal fluid. J Clin Microbiol 38: 3214-3218.
50. Berges BK, Wolfe JH, Fraser NW, (2007) Transduction of brain by herpes simplex virus vectors. Mol Ther 15: 20-29.
51. Martino G, Furlan R, Comi G, Adorini L, (2001) The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol 22: 483-490.
52. Kesari S, Lasner TM, Balsara KR, Randazzo BP, Lee VM, et al. (1998) A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J Gen Virol 79 (Pt 3): 525-536.
53. Gierasch WW, Zimmerman DL, Ward SL, Vanheyningen TK, Romine JD, et al. (2006) Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. J Virol Methods 135: 197-206.
54. Baker D, Gerritsen W, Rundle J, Amor S, (2011) Critical appraisal of animal models of multiple sclerosis. Mult Scler 17: 647-657.
55. Banner LR, Moayeri NN, Patterson PH, (1997) Leukemia inhibitory factor is expressed in astrocytes following cortical brain injury. Exp Neurol 147: 1-9.
56. Yoshida T, Satoh M, Nakagaito Y, Kuno H, Takeuchi M, (1993) Cytokines affecting survival and differentiation of an astrocyte progenitor cell line. Brain Res Dev Brain Res 76: 147-150.
57. Cantin E, Hinton D, Chen J, Openshaw H, (1995) Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol 69: 4898-4905.
58. Guo B, Chang E, Cheng G, (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 118: 1680-1690.
59. Prinz M, Schmidt H, Mildner A, Knobeloch K, Hanisch U, et al. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28: 675-686.